Posted by Michael Wonder on 07 Oct 2021
BeiGene announces first regulatory approval in Australia for Brukinsa (zanubrutinib) for treatment of patients with Waldenström’s macroglobulinaemia
7 October 2021 - Represents Brukinsa’s second recent approval in the Asia-Pacific region, following October 1 approval in Singapore for treatment of patients with mantle cell lymphoma.
BeiGene today announced that Brukinsa (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy or in first line treatment for patients unsuitable for chemo-immunotherapy.
Following registration of Brukinsa with the Therapeutic Goods Administration, these patients will have immediate access to Brukinsa through a BeiGene sponsored post-approval, pre-reimbursement access program.
